Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 1:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Skin Cancer Scalp Clear all
Completed Phase 3 Interventional Results available

Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis

NCT01686152
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Imiquimod Cream, 3.75%, Zyclara®, Vehicle of Test Product
Drug · Other
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Tucson, Arizona • Encino, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Jul 22, 2026, 1:30 PM EDT
Not listed Not applicable Interventional Results available

Scalp Cooling to Prevent Chemo-induced Hair Loss

NCT01986140
View directory record Official record
Conditions
Breast Cancer, Alopecia
Interventions
PAXMAN Orbis Scalp Cooler, Control No treatment
Device · Other
Lead sponsor
Julie Nangia
Other
Eligibility
18 Years and older · Female only
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
7
States / cities
Morristown, New Jersey • New York, New York • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

NCT02100813
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Snellville, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jul 22, 2026, 1:30 PM EDT
Active, not recruiting Not applicable Interventional

Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)

NCT06215469
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer, Hair Loss, Alopecia, Chemotherapy-induced Alopecia
Interventions
Amma Portable Scalp Cooling System (PSCS), Questionnaires
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Not applicable Interventional

Efficacy of Paxman Scalp Cooling to Prevent Chemo Induced Alopecia in Black Patients With Breast or GYN Cancers

NCT04626895
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Gynecologic Neoplasm, Endometrial Cancer
Interventions
Paxman Scalp Cooling Device
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jul 22, 2026, 1:30 PM EDT
Withdrawn Phase 3 Interventional

Phase 3 Study of Levulan With New Blue Light for AK on the Face or Scalp

NCT03024060
View directory record Official record
Conditions
Actinic Keratosis
Interventions
ALA, Vehicle, IBL 20 mW, IBL 10 mW
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
7
States / cities
San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Jul 22, 2026, 1:30 PM EDT
Active, not recruiting Not applicable Interventional

CARE (Chemotherapy Alopecia REduction)

NCT07201389
View directory record Official record
Conditions
Breast Cancer, Breast - Female, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Chemotherapy Induced Alopecia
Interventions
Scalp Cooling by DigniCap
Device
Lead sponsor
George Washington University
Other
Eligibility
21 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 22, 2026, 1:30 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

NCT04269395
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
MAL Cream, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

Single-Center Study Evaluating Systemic Exposure and Safety of KX2-391 Ointment 1% on the Face or Balding Scalp in Subjects With Actinic Keratosis

NCT03575780
View directory record Official record
Conditions
Actinic Keratoses
Interventions
KX2-391 Ointment 1%
Drug
Lead sponsor
Athenex, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

NCT02305888
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

NCT02547363
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 gel, Vehicle gel
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Smithtown, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 1 Interventional

Pharmacokinetics of Ingenol Mebutate Gel in Actinic Keratosis Under Maximum Use Conditions

NCT02124239
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol mebutate
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Placebo, KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Mobile, Alabama • Glendale, Arizona • Fremont, California + 27 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Jul 22, 2026, 1:30 PM EDT
Completed No phase listed Observational Results available

Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

NCT05260073
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
Tirbanibulin
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Jul 22, 2026, 1:30 PM EDT
Recruiting Not applicable Interventional

Study to Assess the Ability of the Portable Scalp Cooling System (PSCS) to Prevent Hair Loss

NCT05484973
View directory record Official record
Conditions
Alopecia, Chemotherapy-induced Alopecia, Hair Loss, Breast Cancer
Interventions
AMMA Portalbe Scalp Cooling System
Device
Lead sponsor
Cooler Heads Care Inc.
Government
Eligibility
21 Years and older · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00915551
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 (Ingenol Mebutate) gel, 0.015%, Vehicle Gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Hot Springs, Arizona • Fremont, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period

NCT03116698
View directory record Official record
Conditions
Actinic Keratosis (AK)
Interventions
Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily, Placebo twice daily
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
20
States / cities
Cerritos, California • Fremont, California • Palm Springs, California + 14 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 22, 2026, 1:30 PM EDT
Recruiting Phase 2 Interventional

Scalp Cooling in MBC

NCT04986579
View directory record Official record
Conditions
Metastatic Breast Cancer, Chemotherapy-induced Alopecia
Interventions
Paxman Scalp Cooling System, Eribulin, Sacituzumab govitecan, Trastuzumab deruxtecan
Device · Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 22, 2026, 1:30 PM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

NCT07144345
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Fremont, California • Aventura, Florida • Rolling Meadows, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 22, 2026, 1:30 PM EDT
Not listed Not applicable Interventional

Efficacy and Safety of Dignicap System for Preventing Chemotherapy Induced Alopecia

NCT01831024
View directory record Official record
Conditions
Chemotherapy Adjuvant, Breast Cancer
Interventions
Dignicap System
Device
Lead sponsor
Target Health Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
San Francisco, California • New York, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 2 Interventional Results available

Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

NCT02838628
View directory record Official record
Conditions
Actinic Keratosis
Interventions
50 mg of KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fremont, California • La Mesa, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Results available

An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis

NCT03200912
View directory record Official record
Conditions
ACTINIC KERATOSIS
Interventions
Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
507 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Oceanside, California • Denver, Colorado • Aventura, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest

NCT02361216
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Ingenol Mebutate, Vehicle
Drug · Other
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
729 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Carmel, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Jul 22, 2026, 1:30 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)

NCT03285490
View directory record Official record
Conditions
Actinic Keratosis
Interventions
KX2-391 Ointment 1%, Placebo
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
30
States / cities
Phoenix, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Jul 22, 2026, 1:30 PM EDT